Clinical trial NCT03445741: Efficacy of Various Aerobic Exercises on Abdominal Obesity in Women With Metabolic Syndrome.
Official title: Effects of Different Intensities and Durations of Aerobic Exercise Training and Detraining on Metabolic, Hormonal Responses and Abdominal Obesity in Women With Metabolic Syndrome.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Metabolic Syndrome
Keywords: Aerobic exercise
Metabolic syndrome
Pedometer
Lead sponsor: Pamukkale University
Sponsor class: OTHER
First posted: 2018-02-26
Enrollment: 60
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants are assigned to three groups in parallel for the duration of the study.
Primary purpose: TREATMENT

Brief summary: Objective: To show metabolic and hormonal responses and effects on abdominal obesity of aerobic exercise in different intensity and duration and detraining period in women with metabolic syndrome.

Detailed description: Objective: To show metabolic and hormonal responses and effects on abdominal obesity of aerobic exercise in different intensity and duration and detraining period in women with metabolic syndrome.

Methods: Fifty-one women with metabolic syndrome were divided into three groups: 12 weekly sessions of high intensity supervised treadmill group, respectively, at % 70 of maximum oxygen consumption (group I, n=17), low intensity supervised treadmill group, respectively at % 50 of maximum oxygen consumption (group II, n=17) and walking at low intensity, respectively at % 50 of maximum oxygen consumption with ECEPEDO pedometer (group III, n=17). Target heart rate (HR) corresponding to values of 50-70 % VO2max were determined by the submaximal treadmill test. Group 1 and 2 were instructed walking at their target HR on a treadmill. The number of steps taken in a minute corresponding to target HR was determined by a criterion pedometer and group 3 was instructed walking in this step range recorded to ECE PEDO giving audible feedback. Participants were evaluated by weight, BMI, waist circumference (WC), blood sugar, LDL, HDL and triglyceride; viseral fat, trunk fat and waist circumference by bioelectrical impedance device (VIScan); ergospirometric VO2max at baseline, 12-week and 4-week detraining period.

Eligibility criteria: Inclusion Criteria:

* eligible participants who meet the criteria for inclusion were women with metabolic syndrome diagnosis according to National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria and were 25-65 years old.
* Participants were well communicative, motivated and willing to participate in the study.

Exclusion Criteria:

* The exclusion criteria were presence of uncontrolled hypertension, type 2 diabetes mellitus, atherosclerotic heart disease, using drugs to affect thyroid, lipids metabolism and insulin sensitization, musculoskeletal or systemic diseases contradicting the exercise, a neurological or psychiatric disease affecting cooperation and cognitive function.

Primary outcomes:
measure: *Change from baseline in abdominal viseral fat and trunk fat and measured by VIScan at week 12 and 4-week detraining period.
timeFrame: Week 12 and week 16
measure: *Change from baseline in weight (kilograms) at week 12 and 4- week detraining period.
timeFrame: Week 12 and week 16
measure: *Change from baseline in Epinephrine/Adrenaline parameter at week 12 and 4- week detraining period.
timeFrame: Week 12 and week 16
measure: *Change from baseline in noradrenaline parameter at week 12 and 4- week detraining period.
timeFrame: Week 12 and week 16
measure: *Change from baseline in free fatty acide parameter at week 12 and 4- week detraining period.
timeFrame: Week 12 and week 16
measure: *Change from baseline in oxyntomodulin parameter at week 12 and 4- week detraining period.
timeFrame: Week 12 and week 16
measure: *Change from baseline in glycerol parameter at week 12 and 4- week detraining period.
timeFrame: Week 12 and week 16
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: